PALVELLA THERAPEUTICS, INC.
PALVELLA THERAPEUTICS, INC. (PVLA): 3 pipeline candidates · 1 upcoming catalyst · ~72 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
71.7 months
D/E 0.14 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~13d
3 buys · 15 sells (180d)
A transparent, data-derived signal for PALVELLA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$206.4M
Quarterly Burn
$10.9M
Runway
71.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ptx-022 | Phase 2 |
| qtorin 3.9% rapamycin anhydrous gel | Phase 3 |
| qtorin rapamycin | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$1.53B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 1,153,496 | $143.8M |
| bvf inc/il | 960,989 | $119.8M |
| vanguard capital management llc | 954,588 | $119.0M |
| blackrock, inc. | 686,853 | $85.6M |
| jennison associates llc | 640,611 | $79.9M |
| woodline partners lp | 635,034 | $79.2M |
| state street corp | 458,999 | $57.2M |
| federated hermes, inc. | 433,015 | $54.0M |
| frontier capital management co llc | 374,035 | $46.6M |
| siren, l.l.c. | 257,485 | $32.1M |
Showing top 10 of 182 institutional holders of PALVELLA THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PALVELLA THERAPEUTICS, INC.'s pipeline?
PALVELLA THERAPEUTICS, INC. (PVLA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PALVELLA THERAPEUTICS, INC.'s lead drug candidate?
PALVELLA THERAPEUTICS, INC.'s most advanced tracked candidate is ptx-022 (Phase 2) for Angiokeratomas.
What is PALVELLA THERAPEUTICS, INC.'s next catalyst?
PALVELLA THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN" — expected July 1, 2026.
What is PALVELLA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PALVELLA THERAPEUTICS, INC. has approximately 71.7 months of cash runway.
What is PALVELLA THERAPEUTICS, INC.'s market capitalization?
PALVELLA THERAPEUTICS, INC.'s market capitalization is approximately $1.6B.
Get the full picture on PALVELLA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.